PAVmed Stock Price, News & Analysis (NASDAQ:PAVMU)

$14.53 0.23 (1.61 %)
(As of 01/17/2018 04:00 PM ET)
Previous Close$14.30
Today's Range$14.50 - $14.53
52-Week Range$7.50 - $25.00
Volume300 shs
Average Volume3,571 shs
Market Capitalization$190.81 million
P/E RatioN/A
Dividend YieldN/A


PAVmed Inc. is a medical device company organized to conceive, develop and commercialize a diversified pipeline of products. The Company's products include PortIO, Caldus, CarpX, NextCath, DisappEAR and NextFlo. PortIO is an implantable vascular access device, which does not require accessing the central venous system and does not have an indwelling intravascular component. CarpX is a percutaneous device to treat carpal tunnel syndrome. NextCath is a self-anchoring catheter, which does not require suturing, traditional anchoring techniques or add-on catheter securement devices. The Company's DisappEAR is an Antibiotic-eluting Resorbable Ear Tubes. The Company is engaged in developing and commercializing antibiotic-eluting resorbable ear tubes based on an aqueous silk technology conceived and developed at these institutions. The Company is engaged in developing disposable infusion system with variable flow resistors. Caldus is a disposable tissue ablation device.

Receive PAVMU News and Ratings via Email

Sign-up to receive the latest news and ratings for PAVMU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets-1,189.50%


Outstanding Shares13,310,000

PAVmed (NASDAQ:PAVMU) Frequently Asked Questions

What is PAVmed's stock symbol?

PAVmed trades on the NASDAQ under the ticker symbol "PAVMU."

Who are some of PAVmed's key competitors?

How do I buy PAVmed stock?

Shares of PAVmed can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PAVmed's stock price today?

One share of PAVmed stock can currently be purchased for approximately $14.53.

How big of a company is PAVmed?

PAVmed has a market capitalization of $190.81 million.

How can I contact PAVmed?

PAVmed's mailing address is 1 Grand Central Terminal Ste 4600, NEW YORK, NY 10017-5743, United States. The company can be reached via phone at +1-212-9494319.

MarketBeat Community Rating for PAVmed (PAVMU)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  42
MarketBeat's community ratings are surveys of what our community members think about PAVmed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

PAVmed (NASDAQ:PAVMU) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Earnings History for PAVmed (NASDAQ:PAVMU)

No earnings announcements for this company have been tracked by


PAVmed (NASDAQ:PAVMU) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for PAVmed (NASDAQ:PAVMU)

No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for PAVmed (NASDAQ PAVMU)

No insider trades for this company have been tracked by


PAVmed (NASDAQ PAVMU) News Headlines


SEC Filings


This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


PAVmed (NASDAQ PAVMU) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.